ATE318923T1 - Doppelsträngige parvovirus-vektoren - Google Patents

Doppelsträngige parvovirus-vektoren

Info

Publication number
ATE318923T1
ATE318923T1 AT01948252T AT01948252T ATE318923T1 AT E318923 T1 ATE318923 T1 AT E318923T1 AT 01948252 T AT01948252 T AT 01948252T AT 01948252 T AT01948252 T AT 01948252T AT E318923 T1 ATE318923 T1 AT E318923T1
Authority
AT
Austria
Prior art keywords
duplexed
parvovirus
double stranded
methods
vector
Prior art date
Application number
AT01948252T
Other languages
English (en)
Inventor
Richard Jude Samulski
Douglas M Mccarty
Original Assignee
Univ North Carolina
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ North Carolina filed Critical Univ North Carolina
Application granted granted Critical
Publication of ATE318923T1 publication Critical patent/ATE318923T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/864—Parvoviral vectors, e.g. parvovirus, densovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Separation By Low-Temperature Treatments (AREA)
  • Surface Acoustic Wave Elements And Circuit Networks Thereof (AREA)
  • Control Of Combustion (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT01948252T 2000-06-01 2001-05-31 Doppelsträngige parvovirus-vektoren ATE318923T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US20860400P 2000-06-01 2000-06-01

Publications (1)

Publication Number Publication Date
ATE318923T1 true ATE318923T1 (de) 2006-03-15

Family

ID=22775222

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01948252T ATE318923T1 (de) 2000-06-01 2001-05-31 Doppelsträngige parvovirus-vektoren

Country Status (10)

Country Link
US (4) US7465583B2 (de)
EP (1) EP1290205B1 (de)
JP (1) JP4860886B2 (de)
AT (1) ATE318923T1 (de)
AU (2) AU6972301A (de)
CA (1) CA2410828C (de)
DE (1) DE60117550T2 (de)
ES (2) ES2256265T3 (de)
NZ (1) NZ522840A (de)
WO (1) WO2001092551A2 (de)

Families Citing this family (201)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2308989T3 (es) * 1999-08-09 2008-12-16 Targeted Genetics Corporation Aumento de la expresion de una secuencia nucleotidica heterologa a partir de vectores viricos recombinantes que contienen una secuencia que forman pares de bases intracatenarios.
US8241622B2 (en) * 2001-07-13 2012-08-14 University Of Iowa Research Foundation Adeno-associated virus vectors with intravector heterologous terminal palindromic sequences
EP2438931B1 (de) * 2004-09-22 2013-11-13 St. Jude Children's Research Hospital Verbesserte Expression von Faktor-IX in Gentherapie-Vektoren
CN101237778A (zh) * 2005-07-07 2008-08-06 建新公司 编码超氧化物歧化酶的aav载体
US7943374B2 (en) * 2005-08-21 2011-05-17 Markus Hildinger Super-size adeno-associated viral vector harboring a recombinant genome larger than 5.7 kb
US20090191597A1 (en) * 2006-01-20 2009-07-30 Asklepios Biopharmaceutical, Inc. Enhanced production of infectious parvovirus vectors in insect cells
EP1979485A2 (de) 2006-01-31 2008-10-15 The Board Of Trustees Of The Leland Stanford Junior University Selbstkomplementäre parvovirale vektoren und verfahren zur herstellung und verwendung davon
EP1994043A4 (de) 2006-02-10 2009-05-20 Univ Cincinnati Phosphatasehemmer-protein 1 als regulator der herzfunktion
WO2007120542A2 (en) 2006-03-30 2007-10-25 The Board Of Trustees Of The Leland Stanford Junior University Aav capsid library and aav capsid proteins
WO2007124148A2 (en) * 2006-04-21 2007-11-01 The University Of North Carolina At Chapel Hill Treatment of connective tissue disorders
US20070280906A1 (en) * 2006-06-03 2007-12-06 Ognjen Petras Method to generate mirrored adenoassociated viral vectors
EP2037892B1 (de) 2006-06-19 2015-03-18 Asklepios Biopharmaceutical, Inc. Modifizierte fatkor-viii- und faktor-ix-gene und vektoren für gentherapie
WO2008103755A1 (en) * 2007-02-20 2008-08-28 Mayo Foundation For Medical Education And Research Treating cancer with viral nucleic acid
EP2019143A1 (de) * 2007-07-23 2009-01-28 Genethon Gentherapie des ZNS mit peripher verabreichten AAV-Vektoren
RU2010117178A (ru) * 2007-10-01 2011-11-10 Алькон Рисерч, Лтд. (Us) Опосредованная самокомплементарными aav доставка молекул, интерферирующих рнк для лечения или профилактики глазных заболеваний
EP2058401A1 (de) 2007-10-05 2009-05-13 Genethon Weitverbreitete Genverabreichung an Motorneuronen unter Verwendung einer peripheren Injektion von AAV-Vektoren
CN101173294B (zh) * 2007-10-12 2011-01-26 中山大学 一种基因微链载体及其构建方法和应用
EP2396343B1 (de) 2009-02-11 2017-05-17 The University of North Carolina At Chapel Hill Modifizierte virusvektoren sowie verfahren zu ihrer herstellung und verwendung
MX2011010097A (es) 2009-03-27 2011-10-19 Proyecto Biomedicina Cima Sl Metodos y composiciones para el tratamiento de cirrosis y fibrosis hepatica.
JP5879256B2 (ja) 2009-05-02 2016-03-08 ジェンザイム・コーポレーション 神経変性障害のための遺伝子治療
EP2266588A1 (de) * 2009-06-04 2010-12-29 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Verfahren zur Krebstherapie basierend auf der gleichzeitigen Verabreichung eines Parvovirus und eines Zytokins
EP2524037B1 (de) 2010-01-12 2018-05-16 The University Of North Carolina At Chapel Hill Restriktive umgekehrte endverstärkungen für virusvektoren
WO2011122950A1 (en) 2010-04-01 2011-10-06 Amsterdam Molecular Therapeutics (Amt) Ip B.V. Monomeric duplex aav vectors
US20130171185A1 (en) 2010-07-06 2013-07-04 Ethan Settembre Norovirus derived immunogenic compositions and methods
WO2012109570A1 (en) 2011-02-10 2012-08-16 The University Of North Carolina At Chapel Hill Viral vectors with modified transduction profiles and methods of making and using the same
KR102112002B1 (ko) 2011-04-29 2020-05-18 셀렉타 바이오사이언시즈, 인크. 치료적 단백질에 대해 면역 반응을 감소시키는 관용원성 합성 나노운반체
US9163259B2 (en) * 2012-05-04 2015-10-20 Novartis Ag Viral vectors for the treatment of retinal dystrophy
CN111621507A (zh) 2012-09-28 2020-09-04 北卡罗来纳-查佩尔山大学 靶向少突胶质细胞的aav载体
MX2015005722A (es) 2012-11-05 2016-01-12 Genzyme Corp Composiciones y metodos para el tratamiento de proteinopatias.
EP2935589A1 (de) 2012-12-18 2015-10-28 Novartis AG Zusammensetzungen und verfahren unter verwendung eines an hyaluronan bindenden peptid-tags
PT2968461T (pt) 2013-03-13 2022-12-26 Genzyme Corp Proteínas de fusão que compreendem porções de ligação ao pdgf e ao vegf e seus métodos de utilização
ES2667209T3 (es) 2013-03-14 2018-05-10 Asklepios Biopharmaceutical, Inc. Genes del receptor-1 de VEGF soluble modificado y vectores para terapia génica
AU2014227766B2 (en) 2013-03-15 2018-10-04 The University Of North Carolina At Chapel Hill Methods and compositions for dual glycan binding AAV vectors
EP3517612A1 (de) 2013-03-15 2019-07-31 The University of North Carolina At Chapel Hill Synthetische adenoassoziierte virusinvertierte endwiederholungssequenzen
SG10201912901YA (en) 2013-04-17 2020-02-27 Genzyme Corp Compositions and methods for treating and preventing macular degeneration
WO2014178863A1 (en) 2013-05-01 2014-11-06 Genzyme Corporation Compositions and methods for treating spinal muscular atrophy
LT3013855T (lt) 2013-06-24 2021-01-25 Xiao, Weidong Mutavusio viii faktoriaus kompozicijos ir metodai
RU2705249C2 (ru) * 2013-07-12 2019-11-06 Дзе Чилдрен'З Хоспитал Оф Филадельфия Вектор aav и анализ на нейтрализующие антитела против aav (аденоассоциированного вируса)
ES2739288T3 (es) 2013-09-13 2020-01-30 California Inst Of Techn Recuperación selectiva
WO2015060722A1 (en) 2013-10-24 2015-04-30 Uniqure Ip B.V. Aav-5 pseudotyped vector for gene therapy for neurological diseases
CA2938828A1 (en) 2014-02-06 2015-08-13 Genzyme Corporation Compositions and methods for treating and preventing macular degeneration
FI3628334T3 (fi) 2014-03-21 2023-09-15 Genzyme Corp Geenihoito verkkokalvon pigmenttirappeuma
US10780182B2 (en) 2014-04-25 2020-09-22 The Trustees Of The University Of Pennsylvania Methods and compositions for treating metastatic breast cancer and other cancers in the brain
MX2016014220A (es) 2014-05-02 2017-02-06 Genzyme Corp Vectores de aav para la terapia genica de la retina y el snc.
WO2015175639A1 (en) 2014-05-13 2015-11-19 The Trustees Of The University Of Pennsylvania Compositions comprising aav expressing dual antibody constructs and uses thereof
EP3154560B1 (de) * 2014-06-13 2019-03-13 University of Pittsburgh - Of the Commonwealth System of Higher Education Verfahren und materialien zur erhöhung der viralen vektorinfektiosität
WO2015198243A2 (en) 2014-06-25 2015-12-30 Novartis Ag Compositions and methods for long acting proteins
WO2015198240A2 (en) 2014-06-25 2015-12-30 Novartis Ag Compositions and methods for long acting proteins
CA2957800A1 (en) 2014-09-07 2016-03-10 Selecta Biosciences, Inc. Methods and compositions for attenuating anti-viral transfer vector immune responses
WO2016037931A1 (en) 2014-09-11 2016-03-17 Fundación Para La Investigación Médica Aplicada Nucleic acid constructs and expression vectors for gene therapy of acute porphyrias and other diseases
WO2016044478A1 (en) 2014-09-16 2016-03-24 Genzyme Corporation Adeno-associated viral vectors for treating myocilin (myoc) glaucoma
EP4012035A1 (de) 2014-09-16 2022-06-15 Genzyme Corporation Adeno-assoziierte virale vektoren zur behandlung von myocilin (myoc)-glaukom
MX2017006216A (es) 2014-11-14 2018-08-29 Voyager Therapeutics Inc Composiciones y métodos para tratar la esclerosis lateral amiotrófica (ela).
RU2727015C2 (ru) 2014-11-21 2020-07-17 Дзе Юниверсити Оф Норт Каролина Эт Чепел Хилл Векторы aav, нацеленные на центральную нервную систему
EP3230441A4 (de) * 2014-12-12 2018-10-03 Voyager Therapeutics, Inc. Zusammensetzungen und verfahren zur herstellung von scaav
CA2972807C (en) 2015-01-14 2024-01-16 The University Of North Carolina At Chapel Hill Methods and compositions for targeted gene transfer
IL296391B2 (en) 2015-01-20 2024-06-01 Genzyme Corp Analytical ultracentrifugation for characterization of recombinant viral particles
SG10201907399RA (en) 2015-02-10 2019-09-27 Genzyme Corp Enhanced delivery of viral particles to the striatum and cortex
US10450563B2 (en) 2015-02-10 2019-10-22 Genzyme Corporation Variant RNAi
TWI707951B (zh) 2015-04-08 2020-10-21 美商健臻公司 過大腺相關載體之製造
US10016514B2 (en) 2015-05-15 2018-07-10 New Hope Research Foundation Polynucleotides, vectors and methods for insertion and expression of transgenes
WO2016186772A2 (en) 2015-05-16 2016-11-24 Genzyme Corporation Gene editing of deep intronic mutations
CA2996420A1 (en) 2015-09-28 2017-04-06 The University Of North Carolina At Chapel Hill Methods and compositions for antibody-evading virus vectors
RU2743792C2 (ru) 2015-11-05 2021-02-26 Бамбу Терапьютикс, Инк. Модифицированные гены атаксии фридрейха и векторы для генной терапии
AU2016366549B2 (en) 2015-12-11 2022-11-10 California Institute Of Technology Targeting peptides for directing adeno-associated viruses (AAVs)
LT3411484T (lt) 2016-02-05 2023-11-27 Emory University Viengrandžio arba sau pačiam komplementaraus adeno-asocijuoto viruso 9 injekcija į smegenų skystį
WO2017139381A1 (en) 2016-02-08 2017-08-17 University Of Iowa Research Foundation Methods to produce chimeric adeno-associated virus/bocavirus parvovirus
JP7231922B2 (ja) 2016-02-22 2023-03-02 ザ ユニヴァーシティー オブ ノース カロライナ アト チャペル ヒル Ｍｐｓ－ｉ関連失明の治療のためのａａｖ－ｉｄｕａベクター
CA3016985C (en) 2016-03-07 2023-07-04 University Of Iowa Research Foundation Aav-mediated expression using a synthetic promoter and enhancer
EP3449250B1 (de) 2016-04-28 2020-11-04 Indiana University Research & Technology Corporation Verfahren und zusammensetzungen zur auflösung von komponenten einer viruspräparation
US11504435B2 (en) 2016-06-13 2022-11-22 The University Of North Carolina At Chapel Hill Optimized CLN1 genes and expression cassettes and their use
CA2971303A1 (en) 2016-06-21 2017-12-21 Bamboo Therapeutics, Inc. Optimized mini-dystrophin genes and expression cassettes and their use
EP3491015A4 (de) 2016-07-26 2020-02-26 The University of North Carolina at Chapel Hill Vektorvermittelte immuntoleranz im auge
TN2019000047A1 (en) 2016-08-15 2020-07-15 Genzyme Corp Methods for detecting aav
MA45996A (fr) 2016-08-16 2021-06-02 Bluebird Bio Inc Variants d'endonucléase de homing du récepteur alpha de l'il-10, compositions et méthodes d'utilisation associées
WO2018035451A1 (en) 2016-08-19 2018-02-22 Calimmune, Inc. Methods and compositions for treating conditions using recombinant self-complementary adeno-associated virus
MA46059A (fr) 2016-08-23 2019-07-03 Bluebird Bio Inc Variants de l'endonucléase homing tim3, compositions et procédés d'utilisation
EP4248979A3 (de) 2016-09-08 2023-12-20 2seventy bio, Inc. Pd-1-homing-endonukleasevarianten, zusammensetzungen und verfahren zur verwendung
CA3040157A1 (en) 2016-10-17 2018-04-26 Bluebird Bio, Inc. Tgf.beta.r2 endonuclease variants, compositions, and methods of use
CN117720665A (zh) 2016-11-17 2024-03-19 2赛文缇生物公司 TGFβ信号转换器
WO2018106956A2 (en) 2016-12-07 2018-06-14 University Of Florida Research Foundation, Incorporated IL-1RA CDNAs
US10286087B2 (en) 2016-12-16 2019-05-14 Uniqure Ip B.V. Immunoadsorption
KR20190104194A (ko) 2017-01-07 2019-09-06 셀렉타 바이오사이언시즈, 인크. 합성 나노담체에 커플링된 면역억제제의 패턴화된 투여
US11142775B2 (en) 2017-01-13 2021-10-12 University Of Iowa Research Foundation Bocaparvovirus small noncoding RNA and uses thereof
CN110446781A (zh) 2017-02-15 2019-11-12 蓝鸟生物公司 供体修复模板多重基因组编辑
JP7132934B2 (ja) 2017-03-15 2022-09-07 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル ポリプロイド性アデノ随伴ウイルスベクターならびにその作製および使用の方法
MX2019011599A (es) 2017-03-30 2019-12-19 Univ Queensland Moleculas quimericas y usos de las mismas.
JP2020517238A (ja) * 2017-04-18 2020-06-18 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ アデノ随伴ウイルスベクターの産生方法
CN110913866A (zh) 2017-05-05 2020-03-24 沃雅戈治疗公司 治疗肌萎缩性侧索硬化(als)的组合物和方法
EP3630962A4 (de) 2017-05-25 2021-01-20 Bluebird Bio, Inc. Cblb-endonuklease-varianten, zusammensetzungen und verfahren zur verwendung
EP3685168A1 (de) 2017-09-20 2020-07-29 The Trustees Of Indiana University Verfahren zur auflösung von lipoproteinen mit massenspektrometrie
WO2019060726A1 (en) 2017-09-22 2019-03-28 Genzyme Corporation VARIANT OF ARNI
US11779654B2 (en) 2017-10-04 2023-10-10 2Seventy Bio, Inc. PCSK9 endonuclease variants, compositions, and methods of use
BR112020007157A2 (pt) 2017-10-13 2020-09-24 Selecta Biosciences, Inc. métodos e composições para a atenuação de respostas de igm antivetor de transferência viral
JP7502991B2 (ja) 2017-10-16 2024-06-19 ボイジャー セラピューティクス インコーポレイテッド 筋萎縮性側索硬化症（ａｌｓ）の治療
WO2019094061A1 (en) 2017-11-07 2019-05-16 The University Of North Carolina At Chapel Hill Optimized aga genes and expression cassettes and their use
US11232941B2 (en) 2018-01-12 2022-01-25 The Trustees Of Indiana University Electrostatic linear ion trap design for charge detection mass spectrometry
US10610606B2 (en) 2018-02-01 2020-04-07 Homology Medicines, Inc. Adeno-associated virus compositions for PAH gene transfer and methods of use thereof
WO2019155833A1 (ja) * 2018-02-07 2019-08-15 学校法人日本医科大学 改良型アデノ随伴ウイルスベクター
BR112020016288A2 (pt) * 2018-02-14 2020-12-15 Generation Bio Co. Vetores de dna não virais e usos dos mesmos para produção de anticorpos e proteínas de fusão
JP7244547B2 (ja) 2018-02-19 2023-03-22 ホモロジー・メディシンズ・インコーポレイテッド Ｆ８遺伝子機能を回復させるためのアデノ随伴ウイルス組成物及びその使用の方法
EP3758682A4 (de) 2018-02-26 2021-12-15 Antolrx, Inc. Tolerogene liposome und verfahren zur verwendung davon
JP7406677B2 (ja) 2018-04-03 2023-12-28 ギンコ バイオワークス インコーポレイテッド 抗体を回避するウイルスベクター
KR20210006358A (ko) 2018-04-03 2021-01-18 스트라이드바이오 인코포레이티드 안 조직을 표적으로 하기 위한 바이러스 벡터
CA3095179A1 (en) 2018-04-03 2019-10-10 Stridebio, Inc. Antibody-evading virus vectors
WO2019236143A1 (en) 2018-06-04 2019-12-12 The Trustees Of Indiana University Apparatus and method for calibrating or resetting a charge detector
JP7306727B2 (ja) 2018-06-04 2023-07-11 ザ・トラスティーズ・オブ・インディアナ・ユニバーシティー リアル・タイム分析および信号最適化による電荷検出質量分光分析法
WO2019236139A1 (en) 2018-06-04 2019-12-12 The Trustees Of Indiana University Interface for transporting ions from an atmospheric pressure environment to a low pressure environment
WO2019241685A1 (en) 2018-06-14 2019-12-19 Bluebird Bio, Inc. Cd79a chimeric antigen receptors
CN112639110A (zh) 2018-06-22 2021-04-09 阿斯克肋匹奥生物制药公司 用于基因递送以在细胞内持续存在的载体
US20210269829A1 (en) 2018-06-28 2021-09-02 The University Of North Carolina At Chapel Hill Optimized cln5 genes and expression cassettes and their use
EP3823676A1 (de) 2018-07-16 2021-05-26 Selecta Biosciences, Inc. Verfahren und zusammensetzungen von mma-konstrukten und vektoren
WO2020018583A1 (en) 2018-07-16 2020-01-23 Selecta Biosciences, Inc. Methods and compositions of otc constructs and vectors
WO2020028816A1 (en) 2018-08-03 2020-02-06 Genzyme Corporation Variant rnai against alpha-synuclein
US20210316012A1 (en) 2018-08-10 2021-10-14 The University Of North Carolina At Chapel Hill Optimized cln7 genes and expression cassettes and their use
CA3111076A1 (en) 2018-08-30 2020-03-05 Tenaya Therapeutics, Inc. Cardiac cell reprogramming with myocardin and ascl1
AU2019346447A1 (en) 2018-09-26 2021-04-29 California Institute Of Technology Adeno-associated virus compositions for targeted gene therapy
WO2020069461A1 (en) 2018-09-28 2020-04-02 Voyager Therapeutics, Inc. Frataxin expression constructs having engineered promoters and methods of use thereof
WO2020072059A1 (en) 2018-10-04 2020-04-09 Bluebird Bio, Inc. Cblb endonuclease variants, compositions, and methods of use
CN113194982A (zh) 2018-10-12 2021-07-30 建新公司 通过肝导向基因替代疗法治疗严重pku的改良的人pah的产生
EP3873537A4 (de) * 2018-11-02 2022-10-12 Nikegen Limited Rekombinante parvovirus-vektoren und verfahren zu deren herstellung und verwendung
AU2019384065A1 (en) 2018-11-20 2021-06-03 The Trustees Of Indiana University Orbitrap for single particle mass spectrometry
WO2020142714A1 (en) 2019-01-04 2020-07-09 Exonics Therapeutics, Inc. Aav expression cassette and aav vectors comprising the same
CR20210444A (es) 2019-02-25 2021-11-02 Novartis Ag Composiciones y métodos para tratar distrofia cristalina de bietti
WO2020174369A2 (en) 2019-02-25 2020-09-03 Novartis Ag Compositions and methods to treat bietti crystalline dystrophy
TW202102525A (zh) 2019-03-21 2021-01-16 美商史崔德生物公司 重組腺相關病毒載體
EP3959741A1 (de) 2019-04-23 2022-03-02 The Trustees of Indiana University Identifizierung von probensubspezies basierend auf partikelladungsverhalten unter strukturveränderungen induzierenden probenbedingungen
CN113767110A (zh) 2019-04-26 2021-12-07 北卡罗来纳-查佩尔山大学 用于双重聚糖结合aav2.5载体的方法和组合物
CA3138525A1 (en) 2019-04-28 2020-11-05 Selecta Biosciences, Inc. Methods for treatment of subjects with preexisting immunity to viral transfer vectors
EP3976802A1 (de) 2019-05-28 2022-04-06 Selecta Biosciences, Inc. Verfahren und zusammensetzungen für abgeschwächte immunantwort auf antivirale transfervektoren
WO2020261178A1 (en) 2019-06-27 2020-12-30 Pfizer Inc. Methods of treating duchenne muscular dystrophy using aav mini-dystrophin gene therapy
US20230137971A1 (en) 2019-07-11 2023-05-04 Tenaya Therapeutics Inc. Cardiac cell reprogramming with micrornas and other factors
US20240060989A1 (en) 2019-10-04 2024-02-22 Novartis Ag Methods for measuring cralbp activity
TW202128736A (zh) 2019-10-17 2021-08-01 美商史崔德生物公司 用於治療ｃ型尼曼—匹克病之腺相關病毒載體
CA3159944A1 (en) 2019-12-02 2021-06-10 David HUSS Therapeutic editing
CN113614225A (zh) * 2019-12-17 2021-11-05 耐克基因有限责任公司 细小病毒载体及其制备方法和用途
TW202140791A (zh) 2020-01-13 2021-11-01 美商霍蒙拉奇醫藥公司 治療苯酮尿症之方法
BR112022020444A2 (pt) 2020-04-10 2022-11-29 Sola Biosciences Llc Composições e métodos para o tratamento de distúrbios de agregação de proteínas
US20230111672A1 (en) * 2020-04-27 2023-04-13 The Regents Of The University Of California Compositions and methods for production of recombinant adeno-associated virus
JP2023524414A (ja) 2020-04-28 2023-06-12 ソラ・バイオサイエンシズ・エルエルシー Ｔｄｐ－４３プロテイノパチーの処置のための組成物および方法
CN116096737A (zh) 2020-06-05 2023-05-09 索拉生物科学有限公司 用于治疗突触核蛋白病的组合物和方法
IL299586A (en) 2020-07-16 2023-03-01 Novartis Ag Anti-betacellulin antibodies, their fragments, and multispecific binding molecules
US20230285596A1 (en) 2020-07-27 2023-09-14 Voyager Therapeutics, Inc Compositions and methods for the treatment of niemann-pick type c1 disease
BR112023001456A2 (pt) 2020-07-27 2023-04-11 Voyager Therapeutics Inc Composições e métodos para o tratamento de distúrbios neurológicos relacionados à deficiência de beta glicosilceramidase
TW202229559A (zh) 2020-10-01 2022-08-01 美商健臻公司 藉由肝導向基因替代療法治療pku之人類pah表現匣
EP4225382A2 (de) 2020-10-07 2023-08-16 Asklepios Biopharmaceutical, Inc. Therapeutische adeno-assoziierte virusverabreichung von fkutin-verwandtem protein (fkrp) zur behandlung von dystroglycanopathie. erkrankungen mit gliedmassengürtel 21
US11781156B2 (en) 2020-10-09 2023-10-10 Tenaya Therapeutics, Inc. Plakophillin-2 gene therapy methods and compositions
CN117098771A (zh) 2020-10-26 2023-11-21 索拉生物科学有限公司 用于治疗阿尔茨海默病的组合物和方法
AU2021369480A1 (en) 2020-10-28 2023-04-20 The University Of North Carolina At Chapel Hill Methods and compositions for dual glycan binding AAV2.5 vector
WO2022093769A1 (en) 2020-10-28 2022-05-05 The University Of North Carolina At Chapel Hill Methods and compositions for dual glycan binding aav2.5 vector
MX2023005218A (es) 2020-11-03 2023-05-16 Pfizer Metodos de purificacion de vectores de aav mediante cromatografia de intercambio anionico.
AU2021404944A1 (en) 2020-12-23 2023-07-06 Pfizer Inc. Methods for purification of aav vectors by affinity chromatography
AU2022206197A1 (en) 2021-01-05 2023-07-13 Selecta Biosciences, Inc. Viral vector dosing protocols
TW202242124A (zh) 2021-01-14 2022-11-01 美商史崔德生物公司 靶向ｔ細胞之ａａｖ載體
US11760788B2 (en) 2021-03-02 2023-09-19 Pathways Neuro Pharma, Inc. Neuroreceptor compositions and methods of use
CN117460832A (zh) 2021-03-22 2024-01-26 建新公司 空aav衣壳和完整aav衣壳的尺寸排阻色谱分析
JP2024511851A (ja) 2021-03-30 2024-03-15 エーエーブイネルジーン インク． 改変血漿凝固第ｖｉｉｉ因子およびその使用方法
US11795207B2 (en) 2021-03-30 2023-10-24 AAVnerGene Inc. Modified plasma clotting factor VIII and method of use thereof
US20240189447A1 (en) 2021-04-16 2024-06-13 Asklepios Biopharmaceutical, Inc. Rational polyploid aav virions that cross the blood brain barrier and elicit reduced humoral response
WO2022232178A1 (en) 2021-04-27 2022-11-03 4D Molecular Therapeutics Inc. Compositions and methods for treatment of ocular disease associated with angiogenesis
WO2022269466A1 (en) 2021-06-22 2022-12-29 Pfizer Inc. Production of adeno-associated virus vector in insect cells
AU2022299552A1 (en) 2021-06-25 2024-01-04 Oxford Biomedica (Us) Llc Adeno-associated virus packaging systems
AU2022310862A1 (en) 2021-07-14 2024-02-01 Regeneron Pharmaceuticals, Inc. Engineered t cell receptors fused to binding domains from antibodies
EP4377459A2 (de) 2021-07-30 2024-06-05 Tune Therapeutics, Inc. Zusammensetzungen und verfahren zur modulation der expression von frataxin (fxn)
WO2023010135A1 (en) 2021-07-30 2023-02-02 Tune Therapeutics, Inc. Compositions and methods for modulating expression of methyl-cpg binding protein 2 (mecp2)
EP4392016A1 (de) 2021-08-24 2024-07-03 Oxford Biomedica (US) LLC Adeno-assoziierte virusformulierungen
CA3234720A1 (en) 2021-10-08 2023-04-13 Sola Biosciences Llc Compositions and methods for the treatment of p53-mediated cancers
WO2023060221A2 (en) 2021-10-08 2023-04-13 Sola Biosciences Llc Compositions and methods for the treatment of proteopathies
WO2023064350A1 (en) 2021-10-12 2023-04-20 Selecta Biosciences, Inc. Viral vector dosing protocols
US20230141563A1 (en) 2021-10-12 2023-05-11 Selecta Biosciences, Inc. Methods and compositions for attenuating anti-viral transfer vector igm responses
WO2023069987A1 (en) 2021-10-20 2023-04-27 University Of Rochester Rejuvenation treatment of age-related white matter loss cross reference to related application
US20230183658A1 (en) 2021-10-29 2023-06-15 Oxford Biomedica Solutions Llc Methods and compositions for the purification of adeno-associated virus
WO2023081633A1 (en) 2021-11-02 2023-05-11 University Of Rochester Tcf7l2 mediated remyelination in the brain
CA3237037A1 (en) 2021-11-14 2023-05-19 Cartesian Therapeutics, Inc. Multiple dosing with viral vectors
WO2023091949A2 (en) 2021-11-17 2023-05-25 Voyager Therapeutics, Inc. Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency
WO2023114816A1 (en) 2021-12-14 2023-06-22 Neurogene, Inc. Recombinant optimized galc constructs and methods for treating galc-associated disorders
WO2023114901A2 (en) 2021-12-15 2023-06-22 Oxford Biomedica Solutions Llc Methods and compositions for the production of adeno-associated virus
WO2023139496A1 (en) 2022-01-21 2023-07-27 Pfizer Inc. Gene therapy for gaucher disease
GB202201242D0 (en) 2022-01-31 2022-03-16 Univ Edinburgh Recombinant optimized mecp2 cassettes and methods for treating rett syndrome and related disorders
WO2023150687A1 (en) 2022-02-04 2023-08-10 Ginkgo Bioworks, Inc. Recombinant adeno-associated virus vectors, and methods of use thereof
US20230357437A1 (en) 2022-03-09 2023-11-09 Selecta Biosciences, Inc. Immunosuppressants in combination with anti-igm agents and related dosing
WO2023194796A2 (en) 2022-04-04 2023-10-12 Vectory B.V. Recombinant aav capsid proteins
US20230365968A1 (en) 2022-04-06 2023-11-16 Genzyme Corporation Targeted gene therapy for dm-1 myotonic dystrophy
WO2023196997A2 (en) 2022-04-08 2023-10-12 2Seventy Bio, Inc. Multipartite receptor and signaling complexes
WO2023201207A1 (en) 2022-04-11 2023-10-19 Tenaya Therapeutics, Inc. Adeno-associated virus with engineered capsid
US20230407255A1 (en) 2022-04-12 2023-12-21 Genzyme Corporation Dendritic cell assay for innate immunogenicity to gene therapy agents
WO2023201274A1 (en) 2022-04-12 2023-10-19 Genzyme Corporation Use of an irak4 modulator for gene therapy
TW202400250A (zh) 2022-04-12 2024-01-01 美商健臻公司 Irak4調節劑於基因療法之用途(一)
GB202206336D0 (en) 2022-04-29 2022-06-15 Univ Edinburgh Recombinant therapeutic FMR1 constructs and methods of treating fragile X syndrome and related disorders
WO2023225481A1 (en) 2022-05-16 2023-11-23 Genzyme Corporation Methods of treating metachromatic leukodystrophy
WO2023230512A1 (en) 2022-05-26 2023-11-30 2Seventy Bio, Inc. Compositions for maintaining lentiviral vector and uses thereof
WO2023240236A1 (en) 2022-06-10 2023-12-14 Voyager Therapeutics, Inc. Compositions and methods for the treatment of spinal muscular atrophy related disorders
WO2023242633A2 (en) 2022-06-14 2023-12-21 Vectory B.V. Recombinant aav capsid proteins
WO2023248008A2 (en) 2022-06-20 2023-12-28 Vectory B.V. Degron fusion constructs
WO2024003687A1 (en) 2022-06-28 2024-01-04 Pfizer Inc. Nucleic acids encoding acid alpha-glucosidase (gaa) and vectors for gene therapy
WO2024015881A2 (en) 2022-07-12 2024-01-18 Tune Therapeutics, Inc. Compositions, systems, and methods for targeted transcriptional activation
WO2024036324A1 (en) 2022-08-11 2024-02-15 Selecta Biosciences, Inc. Compositions and methods related to immunoglobulin proteases and fusions thereof
WO2024038365A1 (en) 2022-08-16 2024-02-22 Pfizer Inc. Methods for purification of aav vectors by anion exchange chromatography
WO2024075012A1 (en) 2022-10-06 2024-04-11 Pfizer Inc. Improved host cells for aav vector production
WO2024100633A1 (en) 2022-11-13 2024-05-16 Alexion Pharma International Operations Limited Gene therapy for frontotemporal dementia
WO2024124019A2 (en) 2022-12-07 2024-06-13 Ginkgo Bioworks, Inc. Aav vectors targeting hematopoietic stem cells

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869305A (en) 1992-12-04 1999-02-09 The University Of Pittsburgh Recombinant viral vector system
US6281010B1 (en) 1995-06-05 2001-08-28 The Trustees Of The University Of Pennsylvania Adenovirus gene therapy vehicle and cell line
DE69840439D1 (de) 1997-04-24 2009-02-26 Univ Washington Zielgerichtete genveraenderung mit parvoviralen vektoren
US6156303A (en) 1997-06-11 2000-12-05 University Of Washington Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom
IL121676A0 (en) 1997-09-01 1998-02-22 Yeda Res & Dev Parvovirus vectors
WO2000024917A1 (en) 1998-10-28 2000-05-04 University Of Washington Targeted gene modification by parvoviral vectors
CA2309313A1 (en) 1999-08-05 2001-02-05 Board Of Trustees Of The University Of Arkansas Stimulation of the immune response by human dendritic cell manipulation
ES2308989T3 (es) * 1999-08-09 2008-12-16 Targeted Genetics Corporation Aumento de la expresion de una secuencia nucleotidica heterologa a partir de vectores viricos recombinantes que contienen una secuencia que forman pares de bases intracatenarios.

Also Published As

Publication number Publication date
JP4860886B2 (ja) 2012-01-25
DE60117550T2 (de) 2006-12-07
US20100310516A1 (en) 2010-12-09
EP1290205A2 (de) 2003-03-12
ES2256265T3 (es) 2006-07-16
CA2410828C (en) 2012-01-24
AU6972301A (en) 2001-12-11
NZ522840A (en) 2004-12-24
CA2410828A1 (en) 2001-12-06
AU2001269723B2 (en) 2006-06-29
US20040029106A1 (en) 2004-02-12
US7790154B2 (en) 2010-09-07
DE60117550D1 (de) 2006-04-27
US8361457B2 (en) 2013-01-29
EP1290205B1 (de) 2006-03-01
WO2001092551A3 (en) 2002-08-01
WO2001092551A2 (en) 2001-12-06
US20130252325A1 (en) 2013-09-26
JP2004500858A (ja) 2004-01-15
ES2505700T3 (es) 2014-10-10
AU2001269723B9 (en) 2006-11-16
US20070110724A1 (en) 2007-05-17
US7465583B2 (en) 2008-12-16
US8784799B2 (en) 2014-07-22

Similar Documents

Publication Publication Date Title
ATE318923T1 (de) Doppelsträngige parvovirus-vektoren
DK0702085T3 (da) Rekombinant infektiøs ikke-segmenteret negativ-strenget RNA-virus
WO2002002624A3 (en) B7-like molecules and uses thereof
ATE443074T1 (de) Zubereitungen und methoden zur verwendung in rekombinatorischem klonen von nukleinsäuren
AU2001261063A1 (en) Dna sequences encoding dystrophin minigenes and methods of use thereof
WO2002024891A3 (en) B7-like molecules and uses thereof
ATE398676T2 (de) Antagonistische selektive bindungsagenzien des osteoprotegerin-bindungsproteins
ATE389016T2 (de) Sirna knockout prüfverfahren und konstrukte
ATE482234T1 (de) Antikörper gegen kdr, deren herstellung und verwendungen
ATE484596T1 (de) Mutantes herpes-simplex-virus und verwendung davon bei der behandlung von plattenepithelkarzinom
WO2005033321A3 (en) Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor
CY1106334T1 (el) Βελτιστοποιημενου κωδικονιου αλληλουχιες ιου θηλωματος
WO2001057251A3 (en) Methods and apparatus for predicting, confirming, and displaying functional information derived from genomic sequence
WO2002014485A3 (en) Kallikrein gene
MXPA02012743A (es) Moleculas tipo il-17 y usos de las mismas.
WO2002086144A3 (en) Compositions and methods for recombinational cloning of nucleic acid molecules
DE60207890D1 (de) Neue verbindungen
MXPA03001930A (es) Moleculas pseudorreceptoras de factor de necrosis tumoral y uso de las mismas.
WO2002074807A3 (en) Chimpanzee erythropoietin (chepo) - immunoadhesins
DK1425404T3 (da) Vaccinia-MVA-E3L-mutanter og anvendelse deraf
WO2000053776A3 (en) Human kallikrein-like genes
AU5460900A (en) Infectious cdna clone of gb virus b and uses thereof
EP1626091A3 (de) Doppelsträngige Parvovirus-Vektoren
PL374550A1 (en) Il-17 like molecules and uses thereof
WO2002097046A3 (en) B7 related protein-2 molecules and uses thereof

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties